Abstract
OBJECTIVE--To determine the comparative efficacy and cost benefit of prophylactic monthly (perimenstrual) clotrimazole, versus empiric self-treatment with the same agent at the onset of symptoms in recurrent vulvovaginal candidiasis. DESIGN--Prospective, randomised, open cross-over study of women with proven recurrent vulvovaginal candidiasis. Clinical and microbiological assessments were done every two months for 12 months. SETTING--Women's Clinic of a University Teaching Hospital. SUBJECTS--Twenty-three otherwise healthy, non-pregnant women with greater than four proven episodes of candida vaginitis in the last year were enrolled into the study. INTERVENTION--Patients were randomised to receive: (1) a single dose of prophylactic clotrimazole 500 mg ovule just before or on the last day of the menses each month for 6 months; (2) or a single dose of clotrimazole 500 mg ovule empirically at the onset of symptoms for 6 months. After the first 6 months patients were crossed-over to the opposite regimen. MAIN OUTCOME MEASURES--Symptoms of recurrent vulvovaginitis during each period, and number of clotrimazole ovules used for each 6 month period. The personal preference of the patients for the two different regimens were assessed at the end of study. RESULTS--During the prophylactic 6 months period of the study, 23 patients had 50 episodes of symptomatic vaginitis (mean 2.2 episodes per patient), versus 86 episodes (mean 3.7 episodes/patient) during the empiric self-treatment 6 months period (P = 0.05). However, during the prophylactic period a total of 168 clotrimazole ovules were used (mean 7.3 per patient), versus 84 ovules (mean 3.6 per patient) during the empiric self-treatment period, p < 0.001. The personal preference of the patients for the type of regimen employed were 17 (73.9%) in favour of the empirical treatment, versus 4 (17.4%) in favour of the prophylactic treatment and 2 (8.7%) no personal preference, p < 0.01. CONCLUSION--Empiric self-treatment is more cost-effective and preferable to patients than cyclical monthly prophylactic use of 500 mg clotrimazole vaginal ovules.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davidson F., Mould R. F. Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis. 1978 Jun;54(3):176–183. doi: 10.1136/sti.54.3.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fong I. W., McCleary P., Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol. 1992 Mar;166(3):887–890. doi: 10.1016/0002-9378(92)91356-f. [DOI] [PubMed] [Google Scholar]
- Fong I. W. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med. 1992 Dec;68(6):374–377. doi: 10.1136/sti.68.6.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sobel J. D. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med. 1986 Dec 4;315(23):1455–1458. doi: 10.1056/NEJM198612043152305. [DOI] [PubMed] [Google Scholar]
- Sobel J. D. Vulvovaginal candidiasis--what we do and do not know. Ann Intern Med. 1984 Sep;101(3):390–392. doi: 10.7326/0003-4819-101-3-390. [DOI] [PubMed] [Google Scholar]